Registration Dossier

Diss Factsheets

Toxicological information

Endpoint summary

Currently viewing:

Administrative data

Description of key information

No skin sensitisation study with barium dibenzoate is available, thus the skin sensitisation potential will be addressed with existing data on the individual moieties barium and benzoate.

Barium dibenzoate is not expected to show signs of dermal sensitisation, since the two moieties barium and benzoate have not shown any skin sensitisation potential in experimental testing.

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

Barium dibenzoate is not expected to show signs of dermal sensitisation, since the two moieties barium and benzoate have not shown any skin sensitisation potential in experimental testing. Thus, barium dibenzoate is not to be classified according to regulation (EC) 1272/2008 as skin sensitising. Further testing is not required. For further information on the toxicity of the individual assessment entities, please refer to the relevant sections in the IUCLID and CSR.

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

As the two moieties of barium dibenzoate are not sensitising, barium dibenzoate in all probability has also no sensitising activity.

According to the criteria of REGULATION (EC) No 1272/2008 and its subsequent adaptions, barium dibenzoate does not have to be classified and has no obligatory labelling requirement for sensitization by skin contact.

Categories Display